Deutsche Bank AG Has $4.87 Million Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Deutsche Bank AG boosted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 17.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 258,964 shares of the biotechnology company’s stock after purchasing an additional 37,686 shares during the period. Deutsche Bank AG’s holdings in Arrowhead Pharmaceuticals were worth $4,869,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Avoro Capital Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 25.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company’s stock worth $208,889,000 after purchasing an additional 2,222,223 shares during the last quarter. Norges Bank acquired a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $38,622,000. Slate Path Capital LP raised its stake in shares of Arrowhead Pharmaceuticals by 7.1% in the fourth quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company’s stock worth $98,362,000 after acquiring an additional 347,000 shares during the last quarter. Balyasny Asset Management L.P. lifted its position in shares of Arrowhead Pharmaceuticals by 266.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 372,749 shares of the biotechnology company’s stock worth $7,008,000 after purchasing an additional 270,897 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in shares of Arrowhead Pharmaceuticals by 63.1% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 632,214 shares of the biotechnology company’s stock valued at $11,886,000 after purchasing an additional 244,527 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 50,800 shares of the firm’s stock in a transaction dated Friday, April 11th. The stock was sold at an average price of $11.49, for a total transaction of $583,692.00. Following the sale, the chief executive officer now owns 3,921,255 shares of the company’s stock, valued at $45,055,219.95. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 275,880 shares of company stock worth $4,034,037. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $15.71 on Monday. The stock has a market cap of $2.17 billion, a P/E ratio of -3.04 and a beta of 0.89. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $9.57 and a 1 year high of $30.41. The stock’s 50-day moving average price is $13.30 and its two-hundred day moving average price is $17.78. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analyst estimates of $116.27 million. During the same quarter in the prior year, the business earned ($1.02) earnings per share. On average, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Citigroup reduced their price objective on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. B. Riley reiterated a “buy” rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Finally, StockNews.com raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 14th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.13.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.